Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study

被引：0
|
作者：
Gane, Edward [1 ]
Dunbar, P. Rod [2 ,3 ]
Brooks, Anna [2 ,3 ]
Zhao, Yang [4 ]
Tan, Susanna [4 ]
Lau, Audrey [4 ]
Yang, Jenny [4 ]
Gaggar, Anuj [4 ]
Subramanian, Mani [4 ]
Kottilil, Shyamasundaran [5 ]
Tang, Lydia [5 ]
机构：
[1] Auckland City Hosp, Auckland, New Zealand
[2] Univ Auckland, Sch Biol Sci, Auckland, New Zealand
[3] Univ Auckland, Maurice Wilkins Ctr, Auckland, New Zealand
[4] Gilead Sci Inc, Foster City, CA USA
[5] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
来源：
JOURNAL OF HEPATOLOGY | 2020年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
AS071
引用
收藏
页码：S52 / S52
页数：1
相关论文
共 50 条
  • [21] Discovery of GS-9688 (Selgantolimod) as a Potent and Selective Oral Toll-Like Receptor 8 Agonist for the Treatment of Chronic Hepatitis B
    Mackman, Richard L.
    Mish, Michael
    Chin, Gregory
    Perry, Jason K.
    Appleby, Todd
    Aktoudianakis, Vangelis
    Metobo, Sammy
    Pyun, Peter
    Niu, Congrong
    Daffis, Stephane
    Yu, Helen
    Zheng, Jim
    Villasenor, Armando G.
    Zablocki, Jeff
    Chamberlain, Jason
    Jin, Haolun
    Lee, Gary
    Suekawa-Pirrone, Kimberley
    Santos, Rex
    Delaney, William E.
    Fletcher, Simon P.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (18) : 10188 - 10203
  • [22] EFFECTIVENESS AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE FUMARATE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B VIRUS INFECTED PATIENTS WITH OSTEOPOROSIS RISK: 24 WEEKS AND 48weeks RESULTS OF A REAL-WORLD STUDY
    Li, Hui
    Wei, Jia
    Li, Chunmei
    Liu, Yunhua
    Wang, Hongyan
    Luo, Xinghua
    Gong, Ming
    [J]. HEPATOLOGY, 2021, 74 : 478A - 478A
  • [23] Potential biomarkers of response in chronic hepatitis B patients who achieved HBeAg loss upon treatment with toll-like receptor 8 (TLR8) agonist
    Chen, Diana
    Kim, Sam
    Brooks, Anna
    Zhang, Liao
    Podlaha, Ondrej
    Yang, Jenny
    Gaggar, Anuj
    Dunbar, P. Rod
    Wallin, Jeffrey
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S571 - S572
  • [24] Safety and Pharmacodynamics of Oral TLR-7 agonist GS-9620 in patients with Chronic Hepatitis B
    Gane, Edward J.
    Sicard, Eric
    Gordon, Stuart C.
    Gruener, Daniel
    Roberts, Stuart K.
    Kim, Suzanne
    Cheng, Wendy
    Coffin, Carla S.
    Fedorak, Richard
    Kwo, Paul Y.
    Leggett, Barbara A.
    Lau, Daryl
    Lim, Young-Suk
    Pflanz, Stefan
    Massetto, Benedetta
    Subramanian, Mani
    McHutchison, John G.
    Freilich, Bradley
    Visvanathan, Kumar
    [J]. HEPATOLOGY, 2013, 58 : 661A - 662A
  • [25] Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study
    Janssen, Harry
    Lampertico, Pietro
    Chen, Chi-Yi
    Heo, Jeong
    Fournier, Claire
    Ahn, Sang Hoon
    Tsang, Tak Yin Owen
    Coffin, Carla
    Reggiani, Giulio Marchesini
    Huang, Yi-Hsiang
    Hui, Aric Josun
    Elkhashab, Magdy
    Chen, Chien-Hung
    Jafri, Syed Mohammed Raza
    Tan, Susanna
    Mo, Shuyuan
    Suri, Vithika
    Flaherty, John F.
    Gaggar, Anuj
    Subramanian, Mani
    Agarwal, Kosh
    Chuang, Wan-Long
    Gane, Edward
    Lim, Young-Suk
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S866 - S867
  • [26] Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: week 48 results from a phase 2 open label study
    Lim, Young-Suk
    Lin, Chun-Yen
    Heo, Jeong
    Bae, Ho
    Chuang, Wan-Long
    Hui, Aric Josun
    Elkhashab, Magdy
    Trinh, Huy
    Tan, Susanna
    Mo, Shuyuan
    Flaherty, John F.
    Suri, Vithika
    Gaggar, Anuj
    Subramanian, Mani
    Tsang, Tak Yin Owen
    Ryder, Stephen
    Andreone, Pietro
    Janssen, Harry
    [J]. JOURNAL OF HEPATOLOGY, 2020, 73 : S872 - S872
  • [27] Safety and Efficacy of Switching to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients With Hepatic Impairment: Week 48 Results From a Phase 2 Open Label Study
    Bae, Ho S.
    Lim, Young-Suk
    Trinh, Huy
    Heo, Jeong
    Chuang, Wan-Long
    Hui, Aric Josun
    Elkhashab, Magdy
    Tan, Susanna K.
    Mo, Shuyuan
    Guion, Matthew
    Jump, Belinda
    Flaherty, John
    Suri, Vithika
    Gaggar, Anuj
    Tsang, Tak Yin Owen
    Andreone, Pietro
    Janssen, Harry
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2020, 115 : S567 - S567
  • [28] EFFICACY AND SAFETY OF COMBINATION TREATMENT OF TLR7 AGONIST TQA3334 AND ANTI-PD-L1 TQB2450 IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS: A PILOT RCT PHASE I I STUDY ( OCEAN cure05 STUDY)
    Wu, Ting
    Wu, Di
    Chen, Yuying
    Huang, Da
    Yuan, Zhize
    Wang, Peng
    Xu, Zhongnan
    Wang, Shuna
    Huo, Dandan
    Yan, Weiming
    Han, Meifang
    Ning, Qin
    Wang, Xiaojing
    [J]. HEPATOLOGY, 2023, 78 : S567 - S568
  • [29] Randomized phase II study of GS-4774 as a therapeutic vaccine in virally suppressed patients with chronic hepatitis B
    Lok, Anna S.
    Pan, Calvin Q.
    Han, Steven-Huy B.
    Trinh, Huy N.
    Fessel, W. Jeffrey
    Rodell, Timothy
    Massetto, Benedetta
    Lin, Lanjia
    Gaggar, Anuj
    Subramanian, G. Mani
    McHutchison, John G.
    Ferrari, Carlo
    Lee, Hannah
    Gordon, Stuart C.
    Gane, Edward J.
    [J]. JOURNAL OF HEPATOLOGY, 2016, 65 (03) : 509 - 516
  • [30] Efficacy and safety of celecoxib add on nucleos (t)ide analogues on the hepatitis B surface antigen of virally suppressed patients with chronic hepatitis B-interim analysis
    Xue, Feng
    Li, Yingying
    Zhang, Jing
    Ye, Qing
    Rao, Huiying
    Cao, Zhenhuan
    Li, Jun
    Li, Xiaohe
    Wei, Lai
    [J]. JOURNAL OF HEPATOLOGY, 2023, 78 : S1163 - S1164
12345